These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 15526004)

  • 41. Association analysis of single nucleotide polymorphisms of proinflammatory cytokine and their receptors genes with rheumatoid arthritis in northwest Chinese Han population.
    You CG; Li XJ; Li YM; Wang LP; Li FF; Guo XL; Gao LN
    Cytokine; 2013 Jan; 61(1):133-8. PubMed ID: 23148991
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
    Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Lack of tumor necrosis factor alpha gene polymorphism -857c/t (rs1799724) association in Pakistani rheumatoid arthritis patients.
    Sadaf T; John P; Bhatti A; Jahangir S; Kiani AK; Gill FA; Malik JM
    Int J Rheum Dis; 2016 Nov; 19(11):1119-1125. PubMed ID: 27126784
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
    Komano Y; Tanaka M; Nanki T; Koike R; Sakai R; Kameda H; Nakajima A; Saito K; Takeno M; Atsumi T; Tohma S; Ito S; Tamura N; Fujii T; Sawada T; Ida H; Hashiramoto A; Koike T; Ishigatsubo Y; Eguchi K; Tanaka Y; Takeuchi T; Miyasaka N; Harigai M;
    J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.
    Seitz M; Wirthmüller U; Möller B; Villiger PM
    Rheumatology (Oxford); 2007 Jan; 46(1):93-6. PubMed ID: 16720636
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis.
    Padyukov L; Lampa J; Heimbürger M; Ernestam S; Cederholm T; Lundkvist I; Andersson P; Hermansson Y; Harju A; Klareskog L; Bratt J
    Ann Rheum Dis; 2003 Jun; 62(6):526-9. PubMed ID: 12759288
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Genetic variation in tumor necrosis factor and the nuclear factor-kappaB canonical pathway and risk of non-Hodgkin's lymphoma.
    Cerhan JR; Liu-Mares W; Fredericksen ZS; Novak AJ; Cunningham JM; Kay NE; Dogan A; Liebow M; Wang AH; Call TG; Habermann TM; Ansell SM; Slager SL
    Cancer Epidemiol Biomarkers Prev; 2008 Nov; 17(11):3161-9. PubMed ID: 18990758
    [TBL] [Abstract][Full Text] [Related]  

  • 48. NA1/NA2 heterozygote of Fcgr3b is a risk factor for progression of IgA nephropathy in Chinese.
    Xu G; He Q; Shou Z; Wang H; Zhang X; Wang Y; Chen Y; Chen J
    J Clin Lab Anal; 2007; 21(5):298-302. PubMed ID: 17847104
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interleukin-6 promoter haplotypes are associated with etanercept response in patients with rheumatoid arthritis.
    Schotte H; Schmidt H; Gaubitz M; Drynda S; Kekow J; Willeke P; Schlüter B
    Clin Rheumatol; 2015 Dec; 34(12):2021-8. PubMed ID: 26526676
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dissection of class III major histocompatibility complex haplotypes associated with rheumatoid arthritis.
    Newton JL; Harney SM; Timms AE; Sims AM; Rockett K; Darke C; Wordsworth BP; Kwiatkowski D; Brown MA
    Arthritis Rheum; 2004 Jul; 50(7):2122-9. PubMed ID: 15248209
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy.
    Bibbo C; Goldberg JW
    Foot Ankle Int; 2004 May; 25(5):331-5. PubMed ID: 15134615
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Interleukin-1β, Interleukin1-Ra, Interleukin-10, and tumor necrosis factor-α polymorphisms in Tunisian patients with rheumatoid arthritis.
    Lagha A; Zidi S; Stayoussef M; Gazouani E; Kochkar R; Kochbati S; Almawi WY; Yacoubi-Loueslati B
    Pathol Biol (Paris); 2015 Sep; 63(4-5):179-84. PubMed ID: 26003199
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association of tumour necrosis factor a, b and c microsatellite polymorphisms with clinical disease activity and induction of remission in early rheumatoid arthritis.
    Laivoranta-Nyman S; Möttönen T; Hannonen P; Korpela M; Kautiainen H; Leirisalo-Repo M; Julkunen H; Luukkainen R; Hakala M; Vuori K; Laine AP; Toivanen A; Ilonen J;
    Clin Exp Rheumatol; 2006; 24(6):636-42. PubMed ID: 17207378
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Etanercept decreases synovial expression of tumour necrosis factor-α and lymphotoxin-α in rheumatoid arthritis.
    Neregård P; Krishnamurthy A; Revu S; Engström M; af Klint E; Catrina AI
    Scand J Rheumatol; 2014; 43(2):85-90. PubMed ID: 24313444
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.
    Weinblatt ME; Kremer JM; Bankhurst AD; Bulpitt KJ; Fleischmann RM; Fox RI; Jackson CG; Lange M; Burge DJ
    N Engl J Med; 1999 Jan; 340(4):253-9. PubMed ID: 9920948
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Methylene tetrahydrofolate reductase, transforming growth factor-β1 and lymphotoxin-α genes polymorphisms and susceptibility to rheumatoid arthritis.
    Shaker OG; Alnoury AM; Hegazy GA; El Haddad HE; Sayed S; Hamdy A
    Rev Bras Reumatol Engl Ed; 2016; 56(5):414-420. PubMed ID: 27692391
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Fc-gamma receptor 3A polymorphism predicts the incidence of urinary tract infection in kidney-transplant recipients.
    Das LK; Ide K; Tanaka A; Morimoto H; Shimizu S; Tanimine N; Tanaka Y; Ohdan H
    Hum Immunol; 2017 Apr; 78(4):357-362. PubMed ID: 28315348
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Genetic variation in tumor necrosis factor and lymphotoxin-alpha (TNF-LTA) and breast cancer risk.
    Gaudet MM; Egan KM; Lissowska J; Newcomb PA; Brinton LA; Titus-Ernstoff L; Yeager M; Chanock S; Welch R; Peplonska B; Trentham-Dietz A; Garcia-Closas M
    Hum Genet; 2007 May; 121(3-4):483-90. PubMed ID: 17216494
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: a multicenter randomized clinical trial.
    Iannone F; La Montagna G; Bagnato G; Gremese E; Giardina A; Lapadula G
    J Rheumatol; 2014 Feb; 41(2):286-92. PubMed ID: 24429167
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
    Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
    J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.